11,000 Shares in Bioverativ Inc (BIVV) Purchased by Hikari Power Ltd

Hikari Power Ltd acquired a new stake in shares of Bioverativ Inc (NASDAQ:BIVV) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,000 shares of the biotechnology company’s stock, valued at approximately $628,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Advisors Asset Management Inc. acquired a new position in shares of Bioverativ during the 3rd quarter valued at about $137,000. TCI Wealth Advisors Inc. acquired a new position in shares of Bioverativ during the 3rd quarter valued at about $186,000. Canada Pension Plan Investment Board acquired a new position in shares of Bioverativ during the 3rd quarter valued at about $194,000. ACG Wealth acquired a new position in shares of Bioverativ during the 3rd quarter valued at about $205,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Bioverativ during the 3rd quarter valued at about $238,000. 95.16% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “11,000 Shares in Bioverativ Inc (BIVV) Purchased by Hikari Power Ltd” was published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://transcriptdaily.com/2017/11/17/11000-shares-in-bioverativ-inc-bivv-purchased-by-hikari-power-ltd.html.

A number of analysts recently issued reports on BIVV shares. Zacks Investment Research downgraded shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Jefferies Group LLC reissued a “buy” rating and set a $70.00 target price (up previously from $67.00) on shares of Bioverativ in a research report on Wednesday, August 9th. Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Wednesday, September 20th. Cowen and Company reissued a “buy” rating and set a $80.00 target price on shares of Bioverativ in a research report on Friday, August 4th. Finally, Evercore ISI started coverage on shares of Bioverativ in a research report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 target price for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $61.73.

Bioverativ Inc (NASDAQ BIVV) traded up $0.11 during midday trading on Friday, reaching $55.29. The company’s stock had a trading volume of 3,538,600 shares, compared to its average volume of 1,624,642. Bioverativ Inc has a 52-week low of $40.00 and a 52-week high of $64.41.

Bioverativ (NASDAQ:BIVV) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. The firm had revenue of $291.60 million during the quarter, compared to analysts’ expectations of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The business’s quarterly revenue was up 27.2% on a year-over-year basis. equities analysts forecast that Bioverativ Inc will post 2.45 earnings per share for the current year.

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply